Skip to content

Non-inferiority Trial of Iontophoretic Corneal Collagen Crosslinking (CXL) Compared to Standard Corneal Collagen Crosslinking in Progressive Keratoconus.

Non-inferiority Trial of Iontophoretic Corneal Collagen Crosslinking (CXL) Compared to Standard Corneal Collagen Crosslinking in Progressive Keratoconus.

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01868620
Acronym
IONTO-CXL
Enrollment
28
Registered
2013-06-04
Start date
2013-05-31
Completion date
2017-03-31
Last updated
2019-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Progressive Keratoconus

Keywords

Progressive keratoconus, standard CXL, iontophoretic CXL, keratometry

Brief summary

The primary purpose of the protocol is to compare the current standard CXL with iontophoretic CXL to provide evidence in relation to the efficacy and safety in progressive keratoconus. Corneal collagen crosslinking (CXL) is the first surgical procedure that appears to halt the progression of keratoconus. In the current standard CXL, the central corneal epithelium must be debrided to efficiently permeate the corneal stroma with riboflavin. The epithelium debridement can cause severe pain, infection and stromal haze. The study hypothesis is that iontophorese CXL is as effective as standard CXL to stabilize a progressive keratoconus.

Detailed description

Keratoconus is a common bilateral progressive corneal ecstatic disease causing visual impairment by inducing irregular astigmatism and corneal opacities. This disorder typically begins during teenage years, progresses until the age of 30 to 40 years and, in severe forms, may need a corneal transplantation. CXL has changed the natural evolution of keratoconus. It creates links between collagen fibrils in order to rigidify the corneal stroma and slow down the progression of keratoconus. The corneal stroma is soaked with a riboflavin solution before being exposed to ultraviolet-A radiation. In the current standard CXL, the central corneal epithelium must be debrided to allow the penetration of riboflavin into the cornea with a risk of side effects, such as pain for the first two post-operative days, temporary loss of visual acuity during the first three months, and serious complications such as infection and stromal opacity due to corneal scarring. Iontophoresis is a non invasive technique in which a weak electric current is used to enhance the penetration of riboflavin into the cornea. The iontophoresis technique could allow intrastromal riboflavin diffusion, while keeping the corneal epithelium on, combining the efficiency of the standard procedure without the side effects of epithelial debridement.

Interventions

DEVICEIontophoretic CXL

Sponsors

University Hospital, Toulouse
Lead SponsorOTHER
Sooft Italia
CollaboratorINDUSTRY
Centre de Référence National du Kératocône
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years old * Corneal thickness ≥ 400 µm * Progressive stage 1 to 3 keratoconus (Krumeich classification)

Exclusion criteria

* Corneal thickness \< 400µm * Stage 4 keratoconus (Krumeich classification) * Concomitant corneal disease * History of corneal surgery

Design outcomes

Primary

MeasureTime frameDescription
The main outcome parameter is the non-inferiority of iontophoretic CXL compared to standard CXL in progressive keratoconusOutcome measure is assessed at 1 year.Measuring maximum keratometry (K-max) derived from computerized videokeratography.

Secondary

MeasureTime frameDescription
Comparison of minimum keratometry3 monthsMeasure assessed by tomographic measurement.

Other

MeasureTime frameDescription
Comparison of visual acuityOutcome measure is assessed at 1 year and at 3 months
Intraoperative comparison of corneal concentration of riboflavinOutcome measure is assessed at 1 year and at 3 months
Comparison of mean keratometryAt 1 yearTomographic measurement.
Comparison of biomechanical parametersOutcome measure is assessed at 1 year and at 3 monthsBy ORA (Ocular Response Analyzer)
Comparison of corneal thicknessOutcome measure is assessed at 1 year and at 3 months for the tomographic measurement.
Comparison of depth of treatmentOutcome measure is assessed at 1 year and at 3 monthsBy tomographic measurement
Comparison of postoperative pain and complications during the follow upOutcome measure is assessed at 1 year and at 3 months

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 12, 2026